Walleye Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Walleye Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-169,000	Closed	-$16.9M	–	5211
2025 Q3	$16.9M	Buy	169,000 +124,000	+276%	+$11.2M	0.06%	310
2025 Q2	$3.73M	Hold	45,000	–	–	0.01%	1070
2025 Q1	$3.65M	Sell	45,000 -12,400	-22%	-$1.11M	0.02%	993
2024 Q4	$5.17M	Sell	57,400 -4,500	-7%	-$436K	0.01%	1046
2024 Q3	$6.12M	Hold	61,900	–	–	0.01%	1024
2024 Q2	$5.74M	Sell	61,900 -159,900	-72%	-$14.3M	0.01%	1185
2024 Q1	$21M	Sell	221,800 -90,000	-29%	-$8.35M	0.04%	400
2023 Q4	$27.8M	Buy	311,800 +50,000	+19%	+$3.71M	0.06%	231
2023 Q3	$19.1M	Buy	261,800 +50,000	+24%	+$3.99M	0.05%	277
2023 Q2	$17.6M	Buy	+211,800	New	+$17.7M	0.06%	199
2022 Q4	–	Sell	-3,000	Closed	-$238K	–	3689
2022 Q3	$238K	Buy	+3,000	New	+$253K	﹤0.01%	1995

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Walleye Capital's XBI Position: Q2 2026 in Review

Walleye Capital opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 12,780 shares worth $2.02M. The stake represents 0.01% of the portfolio and ranks #1505 among its holdings. This is a return to the name: Walleye Capital previously reported a position in XBI as recently as Q4 2024.

Walleye Capital first reported a position in XBI in Q4 2020 and has held it in 6 quarters since. The position peaked at $15.9M in Q3 2024. 934 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Walleye Capital held 12,780 shares of State Street SPDR S&P Biotech ETF worth $2.02M as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Walleye Capital position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.01% of Walleye Capital's portfolio in Q2 2026, its #1505 holding.
Walleye Capital first reported a position in State Street SPDR S&P Biotech ETF in Q4 2020 and has held it in 6 quarters since.
Walleye Capital's State Street SPDR S&P Biotech ETF position peaked at $15.9M in Q3 2024.
934 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.